Camber Pharmaceuticals Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Camber Pharmaceuticals Inc Pharmaceutical Import Records from India — 8 Products, $5.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Camber Pharmaceuticals Inc — Pharmaceutical Importer Profile (2026) | 8 Products, $5.6M Trade | TransData Nexus

Camber Pharmaceuticals Inc

Pharmaceutical Importer · United States · Antivirals Focus · $5.6M Total Trade · DGFT Verified

Camber Pharmaceuticals Inc is a pharmaceutical importer based in United States with a total trade value of $5.6M across 8 products in 7 therapeutic categories. Based on 191 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Camber Pharmaceuticals Inc sources from 5 verified Indian suppliers, with Hetero Labs Limited accounting for 49.3% of imports.

Camber Pharmaceuticals Inc — Import Portfolio & Supplier Network

Camber Pharmaceuticals Inc import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Camber Pharmaceuticals Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Hetero Labs Limited	$23.6M	911	49.3%
Annora Pharma Private Limited	$23.2M	870	48.6%
Aspiro Pharma Limited	$861.1K

What Formulations Does Camber Pharmaceuticals Inc Import?

Formulation	Value	Ships
Hydralazine hcl	$1.3M	30
Dabigatran etexilate mesylate	$845.2K	18
Atomoxetine hcl	$845.0K	33
Oxcarbazepine	$783.1K	16
Levetiracetam	$775.4K	17
Levetiracetam	$723.1K	19
Hydralazine hcl	$712.3K	42
Levocetrizine dhcl 5MG	$690.6K	36
Metoprolol succinate tablet 1000s	$521.3K	19
Cinacalcet hcl	$467.8K	10
Hydralazine hcl 50MG	$451.6K	12
Metoprolol succinate	$451.3K	15
Dabigatran etexilate mesylate capsule	$449.8K	9
Eszopiclone	$449.5K	19
Atomoxetine hcl 80MG	$421.9K	9

Camber Pharmaceuticals Inc imports 555 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acyclovir	Antivirals	$1.8M	35	1.1%	8
2	Valacyclovir	Antivirals	$1.5M	30	1.2%	6
3	Famotidine	Gastrointestinal	$774.1K	66	1.4%	11
4	Torsemide	Diuretics	$423.3K	27	2.3%	5
5	Atovaquone	Antimalarial & Antiparasitic	$400.0K	8	0.0%	9
6	Colchicine	Lipid & Metabolism	$385.5K	17	1.8%	7
7	Linezolid	Advanced Antibiotics	$300.0K	6	0.8%	15
8	Itraconazole	Antifungals	$100.0K	2	0.4%	11

Camber Pharmaceuticals Inc imports 8 pharmaceutical products across 7 categories into United States totaling $5.6M.

Camber Pharmaceuticals Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Camber Pharmaceuticals Inc., established in 2007, is a rapidly growing generics company headquartered in Piscataway, New Jersey. Serving as the U.S. sales and marketing division for its parent company, Hetero Labs Limited, Camber has become one of the fastest-growing generics companies in the United States. Hetero, founded in 1993, is India's largest privately held pharmaceutical company and a global leader in Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), with 36 state-of-the-art manufacturing facilities worldwide.

Camber's mission is to improve the quality of life by providing affordable medications across a broad portfolio of therapeutic areas. The company has demonstrated significant growth, achieving 28 product approvals in 2022 and maintaining a 99% service level for its customers over the past two years. With the support of Hetero, Camber is poised to have a record number of product approvals and launches in 2023.

2Distribution Network

Camber Pharmaceuticals operates a robust distribution network to ensure the timely delivery of its products across the United States. The company has expanded its facilities to meet growing product and inventory demands, moving to a state-of-the-art 60,000-square-foot headquarters and warehouse in 2010. In 2021, Camber further expanded its operations by moving into a significantly larger facility in New Jersey, spanning over 200,000 square feet, to support its rapid growth, bringing the total capacity to 350,000 square feet in the U.S.

This expansion reflects Camber's commitment to maintaining a reliable supply chain and meeting the increasing demand for its products. The company's logistics capabilities are designed to ensure efficient distribution, enabling it to serve a wide geographic area within the United States. While specific details about international distribution are not provided, Camber's parent company, Hetero, has a global presence in over 126 countries, indicating potential for international distribution.

3Industry Role

Camber Pharmaceuticals Inc. plays a significant role in the United States pharmaceutical supply chain as a primary wholesaler and distributor of generic medications. By leveraging its parent company's capabilities in API production and vertical manufacturing, Camber ensures a consistent and reliable supply of high-quality generic drugs to the U.S. market.

The company's focus on vertical integration—from research and development to manufacturing and distribution—enables it to maintain control over the entire supply chain. This approach not only ensures product quality but also allows Camber to respond swiftly to market demands and regulatory changes. By offering a broad portfolio of generic medications, Camber serves various segments of the U.S. healthcare system, including retail pharmacies, hospitals, and government facilities.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Camber Pharmaceuticals Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Camber Pharmaceuticals Inc. demonstrates a high degree of sourcing concentration, with its top five products accounting for 86.1% of its total import value from India. This concentration indicates a strategic focus on specific high-demand medications, which can lead to cost efficiencies and streamlined supply chain management. However, such dependency also introduces risks, particularly if there are disruptions in the supply of these key products.

The shipment data reveals a stable relationship with its primary suppliers, Hetero Labs Limited and Annora Pharma Private Limited, which together account for 97.9% of the total import value. This stability suggests strong partnerships and effective supply chain management. Nonetheless, the limited number of suppliers and the high concentration of imports in a few products could pose challenges if there are changes in supplier capabilities, regulatory issues, or market dynamics affecting these specific medications.

2Supply Chain Resilience

Camber Pharmaceuticals Inc.'s supply chain resilience is closely tied to its parent company, Hetero Labs Limited, which has a global presence in over 126 countries and operates 36 state-of-the-art manufacturing facilities worldwide. This extensive network provides a robust foundation for Camber's supply chain, offering potential backup suppliers and alternative sourcing options.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the approval and monitoring of pharmaceutical products, including imports. The FDA ensures that drugs marketed in the U.S. are safe, effective, and manufactured in compliance with established standards.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for the FDA's regulatory activities. The Drug Enforcement Administration (DEA) also plays a role in regulating controlled substances. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Manufacturers must register with the FDA and comply with Current Good Manufacturing Practice (CGMP) regulations. The FDA recognizes various international standards, including EU GMP, WHO GMP, and PIC/S, provided the manufacturing facilities meet FDA's inspection criteria.

Wholesale distribution authorization is also required, ensuring that distributors operate in compliance with federal and state regulations. This includes maintaining proper records, ensuring product traceability, and adhering to storage and handling standards to guarantee product integrity.

Camber Pharmaceuticals Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Camber Pharmaceuticals Inc.'s product strategy focuses on high-demand therapeutic areas, including antivirals, gastrointestinal medications, and diuretics. The company's import data indicates a significant emphasis on antiviral drugs, which constitute 57.7% of its total import value from India. This focus aligns with global health priorities, as antiviral medications are essential in managing and treating various infectious diseases.

The importation of gastrointestinal and diuretic medications suggests a strategic approach to address prevalent health conditions in the U.S. market. By concentrating on these therapeutic areas, Camber aims to meet the needs of healthcare providers and patients, ensuring access to essential medications.

2Sourcing Profile

Camber Pharmaceuticals Inc. employs a sourcing strategy that leverages its parent company's capabilities in API production and vertical manufacturing. This approach ensures a consistent and reliable supply of high-quality generic drugs. The company's import data indicates a focus on specific therapeutic areas

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Camber Pharmaceuticals Inc

What products does Camber Pharmaceuticals Inc import from India?

Camber Pharmaceuticals Inc imports 8 pharmaceutical products across 7 categories. Top imports: Acyclovir ($1.8M), Valacyclovir ($1.5M), Famotidine ($774.1K), Torsemide ($423.3K), Atovaquone ($400.0K).

Who supplies pharmaceuticals to Camber Pharmaceuticals Inc from India?

Camber Pharmaceuticals Inc sources from 5 verified Indian suppliers. The primary supplier is Hetero Labs Limited (49.3% of imports, $23.6M).

What is Camber Pharmaceuticals Inc's total pharmaceutical import value?

Camber Pharmaceuticals Inc's total pharmaceutical import value from India is $5.6M, based on 191 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Camber Pharmaceuticals Inc focus on?

Camber Pharmaceuticals Inc imports across 7 categories. The largest: Antivirals (57.7%), Gastrointestinal (13.7%), Diuretics (7.5%).

Get Full Camber Pharmaceuticals Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.